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A Naturally Occurring Mutation of the Opsin Gene (T4R) in Dogs Affects
Glycosylation and Stability of the G Protein-Coupled Receptor
Abstract
Rho (rhodopsin; opsin plus 11-cis-retinal) is a prototypical G protein-coupled receptor responsible for the
capture of a photon in retinal photoreceptor cells. A large number of mutations in the opsin gene
associated with autosomal dominant retinitis pigmentosa have been identified. The naturally occurring
T4R opsin mutation in the English mastiff dog leads to a progressive retinal degeneration that closely
resembles human retinitis pigmentosa caused by the T4K mutation in the opsin gene. Using genetic
approaches and biochemical assays, we explored the properties of the T4R mutant protein. Employing
immunoaffinity-purified Rho from affected RHOT4R/T4R dog retina, we found that the mutation abolished
glycosylation at Asn2, whereas glycosylation at Asn15 was unaffected, and the mutant opsin localized
normally to the rod outer segments. Moreover, we found that T4R Rho* lost its chromophore faster as
measured by the decay of meta-rhodopsin II and that it was less resistant to heat denaturation. Detergentsolubilized T4R opsin regenerated poorly and interacted abnormally with the G protein transducin (Gt).
Structurally, the mutation affected mainly the “plug” at the intradiscal (extracellular) side of Rho, which is
possibly responsible for protecting the chromophore from the access of bulk water. The T4R mutation
may represent a novel molecular mechanism of degeneration where the unliganded form of the mutant
opsin exerts a detrimental effect by losing its structural integrity.
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Abstract
Rho (rhodopsin; opsin plus 11-cis-retinal) is a prototypical G protein-coupled receptor responsible
for the capture of a photon in retinal photoreceptor cells. A large number of mutations in the opsin
gene associated with autosomal dominant retinitis pigmentosa have been identified. The naturally
occurring T4R opsin mutation in the English mastiff dog leads to a progressive retinal degeneration
that closely resembles human retinitis pigmentosa caused by the T4K mutation in the opsin gene.
Using genetic approaches and biochemical assays, we explored the properties of the T4R mutant
protein. Employing immunoaffinity-purified Rho from affected RHOT4R/T4R dog retina, we found
that the mutation abolished glycosylation at Asn2, whereas glycosylation at Asn15 was unaffected,
and the mutant opsin localized normally to the rod outer segments. Moreover, we found that T4R
Rho* lost its chromophore faster as measured by the decay of meta-rhodopsin II and that it was less
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resistant to heat denaturation. Detergent-solubilized T4R opsin regenerated poorly and interacted
abnormally with the G protein transducin (Gt). Structurally, the mutation affected mainly the “plug”
at the intradiscal (extracellular) side of Rho, which is possibly responsible for protecting the
chromophore from the access of bulk water. The T4R mutation may represent a novel molecular
mechanism of degeneration where the unliganded form of the mutant opsin exerts a detrimental effect
by losing its structural integrity.
G protein-coupled receptors constitute one of the most important families of signaling
molecules in higher organisms and are also the largest class of cell-surface receptors (1,2).
They represent the primary mechanism by which cells sense and respond to their external
environment. Rho (rhodopsin), a representative member of the largest subfamily A (reviewed
in Refs. 3-7), is the only G protein-coupled receptor whose crystal structure is known (8,9).
Mutations of the genes encoding Rho are frequently associated with a number of pathological
conditions inherited as autosomal dominant or autosomal recessive traits (10), classified into
different classes based on biochemical properties (11,12).
Dominantly inherited diseases can result from (a) haploinsufficiency of a gene, (b) gain of
novel function or uncontrolled activation, and (c) loss of function because of mutant protein
misfolding and aggregation. The type of inheritance implies a strategy for potential
intervention. For example, constitutive activity of K296E and K296M opsin mutants can be
silenced by the addition of retinylamine analog inhibitors (13), whereas the misfolded protein
for the P23H opsin mutant can be stabilized by retinoids, at least in a heterologous expression
system (14,15). The disease-causing mutation T4K in opsin has been identified, but the
molecular mechanism of the pathology caused by this mutant has not been elucidated (16).
The prediction is that such a mutation will prevent the glycosylation at Asn2, one of the two
glycosylation sites in opsin. The effects of glycosylation on the retina and Rho functioning
have been investigated previously (11,17-20). Tunicamycin, which inhibits the biosynthesis
of N-acetylglucosaminylpyrophosphorylpolyisoprenol and thus prevents the formation of the
Asn-linked oligosaccharides of glycoproteins, blocks the glycosylation of opsin in vitro, but
only slightly decreases the polypeptide synthesis and intracellular transport of opsin (18,19).
When expressed in a heterologous system, the T4K mutant displays increased mobility in SDSPAGE experiments, suggesting that one or both sites (Asn2 and/or Asn15) have not been
glycosylated. The T4K mutant also regenerates poorly with 11-cis-retinal and displays low
light-dependent activation of the rod photoreceptor G protein transducin (Gt) (11). The N2Q
mutant has normal properties, whereas non-glycosylated Rho is ineffective in the G protein
activation assay (19). After deglycosylation by peptide N-glycosidase F, Rho has spectral
properties in the dark; and after bleaching, it retains properties similar to those of the native
protein (20). When glycosylation at Asn2 and Asn15 is prevented, Rho inserts properly into the
phospholipid bilayer and can be regenerated with 11-cis-retinal (20,21). It also is properly
synthesized and intracellularly transported (17), but its ability to carry out the light-dependent
activation of Gt is diminished (19).
1

An opportunity to study the mechanism of retinitis pigmentosa (RP) pathogenesis was
presented when the T4R mutation was discovered in the English mastiff dog (22,23). The
affected dogs display a dramatically slowed time course for recovery of rod photoreceptor
function after light exposure and a distinctive topographic pattern of retinal degeneration
(22). Here, we present the properties of T4R Rho isolated from the scarce native tissue. We
conclude that mutation of opsin within the intradiscal region affects the stability of the protein
and the regeneration of mutant Rho, but not its spectral properties. This study reveals that the

1The abbreviations used are: RP, retinitis pigmentosa; DM, n-dodecyl β-D-maltoside; GTPγS, guanosine 5′-O-(3-thiotriphosphate); bis-tris propane, 1,3-bis(tris(hydrox
J Biol Chem. Author manuscript; available in PMC 2006 January 26.

Zhu et al.

Page 3

molecule responsible for the retinal degeneration is opsin, suggesting yet another molecular
mechanism for retinal degeneration.

EXPERIMENTAL PROCEDURES
Animals—All dogs (3–9 months old) studied were from a research colony of mixed-breed dogs
maintained at the Retinal Disease Studies Facility (Kennett Square, PA). RHOT4R/+ and
RHOT4R/T4R dogs derive their mutant RHO allele from English mastiff dogs affected with
autosomal dominant progressive retinal atrophy as described previously (22,23). RPE65−/−
and RPE65+/− dogs derive their mutant allele, a 4-bp deletion in the canine RPE65 (retinal
pigment epithelium protein of 65 kDa) gene, from a briard dog affected with the canine
homolog of Leber's congenital amaurosis (24,25). All dogs used in this study were tested to
determine their genotype at either or both the RHO (22,23) and RPE65 (25) loci as described
previously. To produce RHOT4R/+ RPE65−/− double mutant dogs, an initial crossbreeding was
undertaken between an affected female from the RPE65−/− strain (genotype
RHO+/+RPE65−/−) and a heterozygous affected male from the RHOT4R/+ strain (genotype
RHOT4R/+RPE65+/+). One of their female progeny genotyped as RHOT4R/+RPE65+/− was then
backcrossed to an RPE65−/− male, yielding, among others, RHOT4R/+RPE65−/− double mutant
individuals.
Whole retinas were dissected from eyes enucleated immediately postmortem from dogs that
had been dark-adapted for at least 15 h. The retinas were then immediately frozen in liquid
nitrogen and maintained under cryogenic conditions until analyzed. All such procedures were
undertaken under dim red illumination.
Materials—11-cis-Retinal was a gift from Dr. R. K. Crouch (University of South Carolina)
through a contract with the National Institutes of Health. n-Dodecyl β-D-maltoside (DM) was
purchased from Anatrace Inc. (Maumee, OH). GTPγS was purchased from Sigma. Trypsin
was purchased from Princeton Separation, Inc. (Adelphia, NJ). Monoclonal antibody 1D4
raised against the Rho C terminus was purchased from the National Cell Culture Center
(Minneapolis, MN). Monoclonal antibody B6-30N raised against the Rho N terminus was a
generous gift from Dr. P. A. Hargrave (University of Florida). The anti-Gtα monoclonal
antibody was a generous gift from Dr. H. E. Hamm (Vanderbilt University Medical Center).
The anti-Gtβ polyclonal antibody was a generous gift from Dr. O. G. Kisselev (St. Louis
University School of Medicine). The synthetic peptides were purchased from United
Biochemical Research, Inc. (Seattle, WA). The amount of purified bovine Gt was measured
using a 2-D Quant kit (Amersham Biosciences). The hexyl-agarose resin was purchased from
MP Biomedicals Inc. (Aurora, OH). Other resins and columns for chromatography were
purchased from Amersham Biosciences.
Purification of Rho—Purified anti-Rho C terminus antibody 1D4 (26) was immobilized on
CNBr-activated Sepharose 4B (27), and a 4.6 × 12-mm column was packed with 2 mg of
antibody 1D4/ml of Sepharose beads. All procedures employing Rho or retinoids were
performed under dim red light unless mentioned otherwise. The dog retinas were homogenized
in buffer containing 137 mM NaCl, 5.4 mM Na2HPO4, 2.7 mM KCl, and 1.8 mM KH2PO4 (pH
7.5) with a glass-to-glass homogenizer. Soluble proteins in the supernatant were removed by
centrifugation at 14,000 × g for 5 min, and the pellet was then solubilized in buffer containing
1% DM, 10 mM bis-tris propane, and 500 mM NaCl (pH 7.5). After centrifugation at 125,000 ×
g for 20 min, the supernatant was loaded onto the antibody 1D4-packed immunoaffinity
column, followed by thorough washing with buffer A (0.1% DM, 10 mM bis-tris propane, and
500 mM NaCl (pH 7.5)) at a flow rate of 0.5 ml/min. Finally, purified dog Rho was eluted with
100 μM nonapeptide (TETSQVAPA) in buffer A at room temperature. The purified Rho
concentration was determined using a Hewlett-Packard 8452A UV-visible spectrophotometer.
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Electrophoresis and Immunoblotting—Protein separation was performed on 10% SDSpolyacrylamide gels. Coomassie Blue R-250 staining, silver staining, and immunoblotting
(Immobilon-P polyvinylidene difluoride, Millipore Corp.) were carried out according to
standard protocols. Antibodies 1D4 (26) and B6-30N (28) were used to detect the
corresponding C-terminal and N-terminal epitopes. Alkaline phosphatase-conjugated goat
anti-mouse IgG or goat anti-rabbit IgG (Promega) was used as a secondary antibody. Protein
bands were visualized with the 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
color development substrate (Promega).
Deglycosylation of Rho—Peptide N-glycosidase F (New England Biolabs Inc.) was used for
the Rho deglycosylation experiments. In brief, ∼20 μg of immunoaffinity-purified Rho was
first denatured (according to the manufacturer's protocol) and incubated with 100 units of
peptide N-glycosidase F at 37 °C for 14 h. Because deglycosylated Rho has a faster mobility
on SDS-polyacrylamide gel (21), the samples were then immunoblotted with antibody 1D4 to
confirm the completion of deglycosylation.
Quantification and Stability of Rho—Quantification of dog Rho was carried out
spectrophotometrically. Whole dog retinas were homogenized with a glass-to-glass
homogenizer. After centrifugation at 14,000 × g for 5 min, the pellet was solubilized in buffer
containing 1% DM, 10 mM bis-tris propane, and 150 mM NaCl (pH 7.5). The solubilized mixture
was centrifuged at 125,000 × g for 20 min, and one-fourth of the supernatant was used for
quantification of the Rho concentration by UV-visible spectroscopy. In the stability
experiments, UV-visible absorption spectra of freshly purified Rho samples were measured at
37 °C in the absence or presence of 20 mM NH2OH (pH 7.0). The absorbance was recorded at
504 nm until it dropped below 30% of the initial reading. Standard deviations were calculated
from three sets of data from parallel experiments.
Retinoid Analysis—Retinoids were extracted and derivatized as described previously (29-31).
Samples were analyzed by normal-phase HPLC (Beckman Ultrasphere-Si HP1100 column, 5
μm, 4.6 × 250 mm) using an isocratic solvent system consisting of 0.5% (v/v) ethyl acetate in
hexane for 15 min, followed by 4% ethyl acetate in hexane for 60 min at a flow rate of 1.4 ml/
min at 20 °C. The diode array UV-visible detector was set at 325 nm. Data were analyzed with
Hewlett-Packard Chemstation A.06.03 software.
Isolation of N-terminal Peptides for Mass Spectrometry Analysis—Immunoaffinity-purified
dog T4R Rho was desalted with a D-Salt™ dextran desalting column (Pierce), and the original
buffer was replaced with 50 mM NH4HCO3 (adjusted to pH 7.5). The fractions containing the
majority of Rho were concentrated by lyophilization before SDS-PAGE analysis. After
electrophoresis, the gel was first fixed with a solution of 50% EtOH and 10% AcOH for 1–2
h and then washed overnight with a solution of 50% MeOH and 10% AcOH. The washed gel
was stained with a mixture of 0.02% Coomassie Blue R-250, 20% MeOH, and 10% AcOH
and then destained with a solution of 50% MeOH and 10% AcOH. The protein bands
corresponding to T4R Rho (∼5 μg in total) were excised into small pieces (∼1 × 1 × 1 mm3)
and extensively washed with a solution of 50% MeOH and 5% AcOH. After being dehydrated
with CH3CN and dried in a SpeedVac, the gel pieces were treated for 40 min with 10 mM
dithiothreitol (DTT) in 50 mM NH4HCO3 at 40 °C. The solution was removed, and the gel
pieces were rinsed with 50 mM NH4HCO3, dehydrated with CH3CN, and dried again. The dried
gel pieces were alkylated with 50 mM iodoacetamide in 50 mM NH4HCO3 for 40 min in the
dark at 40 °C. After removal of the solution, the gel pieces were incubated with two rounds of
50 mM NH4HCO3 at room temperature for 10 min each time. Finally, the gel pieces were
dehydrated with CH3CN and digested for 24 h with 0.5 μg of trypsin in 100 μl of 50mM
NH4HCO3 at 37 °C. To extract the digested peptides, the solution was removed, and the
digested gel pieces were incubated with another 100 μl of 50mM NH4HCO3 at room temperature
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for 10 min. The incubation was repeated with two rounds of 50% CH3CN and 5% AcOH and
two rounds of 93% CH3CN and 5% AcOH. The extracts were pooled, dried in a SpeedVac,
and dissolved in 20 μl of solvent A (1% CH3CN and 0.2% AcOH) for liquid
chromatographytandem mass spectrometry (LC-MS/MS) analysis. In a parallel experiment,
10 μg (7.5 nmol) of the synthetic N-terminal T4R Rho peptide Ac-MNGREGPNFYV was
digested with 0.4 μg of trypsin in 20 μl of 50 mM NH4HCO3 at 37 °C for 18 h. The reaction
was stopped by adding 0.8 μl of AcOH, and the resulting mixture was dried in a SpeedVac and
dissolved in solvent A to a final peptide concentration of 1 μM for LC-MS/MS analysis.
Mass Spectrometry—Analysis of the tryptic N-terminal peptide Ac-MNGR (MH1+, m/z
519.2354) was performed by microcolumn electrospray LC-MS/MS. The mass spectrometer
(PE-Sciex API QSTAR PULSAR i Q-TOF) was coupled with a nebulization-assisted
electrospray ionization source (PE-Sciex). The house-made microcolumn (250 μm × 15 cm)
was prepared from fused silica tubing packed with Zorbax SB-C18 (4 μm, 80 Å) using an inline
microfilter as the column outlet frit. An Agilent 1100 series HPLC capillary pump was used
to deliver a flow rate of 4 μl/min with a gradient of 100% solvent A (0.2% AcOH) and 0%
solvent B (90% CH3CN and 0.2% AcOH) for 18 min and then gradually to 0% solvent A and
100% solvent B for another 50 min. Throughout the gradient, the mass spectrometer was
programmed to monitor m/z in the range of 500–550 with a +1 charge only, followed by MS/
MS (unit resolution) with three different preset values of collisional energy for each selected
precursor ion. Similar results were obtained in two independent experiments.
Photosensitivity and Regeneration of the Visual Pigment—UV-visible absorption spectra of
freshly purified dog Rho were first measured at 20 °C. The samples were then bleached at a
20-cm distance (to avoid overheating the sample) with a 60-watt light bulb for 10, 20, 30, and
300 s. Alternative bleaching was done using a long-pass wavelength filter (>490 nm). The
results were comparable under both bleaching conditions. The UV-visible absorption spectra
of the bleached samples were immediately measured after each bleaching. In the experiments
without NH2OH, H2SO4 was added after bleaching the sample for 5 min to adjust the final pH
to 1.9 to trap the retinylidene Lys296. In another set of experiments, neutral NH2OH was added
to reach a final concentration of 20 mM before any bleaching was conducted. In the regeneration
experiments, ∼10 μg of wild-type (WT) or T4R Rho solubilized in 1% DM or 2% digitonin
was bleached thoroughly for 2 min with a Fiber-Lite illuminator at a distance of 15 cm. Next,
11-cis-retinal was added under dim red light, and the formation of Rho was measured
immediately afterward. The final ratio of 11-cis-retinal to Rho was 50:1, which enabled fitting
of the data to a pseudo first-order reaction (PWT < 0.0001, PT4R < 0.0008). The rate constants
calculated for dog WT and T4R Rho were 0.00029 and 0.00001 s−1, respectively.
Limited Proteolysis—Freshly purified dog WT and T4R Rho were quantified by UV-visible
spectroscopy. Half of the samples were bleached by illumination with a Fiber-Lite illuminator
for 5 min at room temperature in the presence of 20 mM neutral NH2OH. Both Rho and the
bleached opsin samples were digested at a 200:1 molar ratio of Rho to tosylphenylalanyl
chloromethyl ketone-treated trypsin (Worthington) in buffer containing 137 mM NaCl, 5.4
mM Na2HPO4, 2.7 mM KCl, and 1.8 mM KH2PO4 (pH 7.5) for 5, 15, 30, or 45 min. The digestion
was terminated by the addition of denaturing loading buffer (350 mM Tris-HCl, 350 mM SDS,
30% (v/v) glycerol, 600 mM dithiothreitol, and 175 μM bromphenol blue), and the resulting
mixture was immediately used for SDS-PAGE or immunoblot analysis.
Rates of meta-Rhodopsin II (Meta II) Decay—All measurements were performed with 0.1
nM dog Rho in a solution of 0.1% DM, 10 bis-tris propane, and 100 mM NaCl (pH 6.0), favoring
the formation of Meta II. A PerkinElmer Life Sciences LS 50B luminescence
spectrophotometer was used to measure the increase in intrinsic Trp fluorescence due to
hydrolysis of the protonated Schiff base and release of all-trans-retinal from Rho (32-34).
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Immunoaffinity-purified Rho was bleached with a Fiber-Lite illuminator for 15 s from a
distance of 15 cm, immediately followed by fluorescence measurements. A thermostat was
applied to stabilize the temperature of the cuvette at 20 °C during the measurement.
Fluorometer slit settings were 2.5 μm at 295 nm for excitation and 8 μm at 330 nm for emission.
Both fitted curves have R2 values >0.99.
Purification of Gt—Gt was extracted from fresh bovine rod outer segment (ROS) membranes.
ROS from 200 bovine retinas were homogenized in 80 ml of ice-cold water. The membrane
suspension was centrifuged at 45,000 × g for 30 min, and the supernatant was collected. This
extraction was repeated twice. The combined supernatant was centrifuged at 45,000 × g for 30
min to remove ROS membrane contamination. The final supernatant was adjusted to contain
10 mM MOPS, 2 mM MgCl2,1mM DTT, and 0.5 mM benzamidine (pH 7.5). This solution was
then loaded onto hexyl-agarose resin (10 × 55 mm) equilibrated with buffer containing 10
mM MOPS (pH 7.5), 2 mM MgCl2, 1 mM DTT, and 0.5 mM benzamidine. Bound proteins were
eluted by stepwise addition of 75 mM NaCl and then 300 mM NaCl in the equilibration buffer.
Fractions eluted with 300 mM NaCl, containing Gt and phosphodiesterase, were dialyzed into
10 mM bis-tris propane, 100 mM NaCl, 1 mM DTT, and 0.5 mM benzamidine and used for
preparing Rho*-Gt complexes. For the Gt activity assay, this protein was further separated from
phosphodiesterase by size exclusion chromatography using a Superdex 200 10/300 GL column
(10 × 300 mm; Amersham Biosciences) equilibrated with 10 mM bis-tris propane (pH 7.5)
containing 100 mM NaCl and 1 mM DTT (pH 7.5).
Gt Binding and Activation Assays—In the binding assay, affinity-purified dog Rho (WT or
T4R mutant) was mixed with an equivalent amount of Gt in 10 mM bis-tris propane (pH 7.5)
containing 100 mM NaCl, 1 mM MgCl2, 1 mM DTT, and 2 mM DM and then bleached and
incubated for 15 min on ice to form the complex. To observe Gt dissociation in the other group
of experiments, equivalent amounts of Gt and opsin were incubated in the same buffer with
100 μM GTPγS on ice for 30 min under room light before loading onto a size exclusion column.
This chromatography was performed on a Superdex 200 10/300 GL column (10 × 300 mm) at
room temperature at a flow rate of 0.4 ml/min using 10 mM bis-tris propane (pH 7.5) containing
100 mM NaCl and 1 mM DTT. The protein concentration of each fraction was determined with
a Cary 50 Bio UV-visible spectrophotometer (Varian Inc., Walnut Creek, CA), and the
fractions were then analyzed by SDS-PAGE and immunoblotting as described above.
In the fluorescence assay of Gt activation, the ratio of Gt to Rho was ∼10:1, with Gt at a
concentration of 250 nM and Rho at 25 nM, within the linear range of fluorescence change and
protein concentrations. The sample was bleached for 15 s using a Fiber-Lite covered with a
long-pass wavelength filter (>490 nm), followed by a 10-min incubation (if not indicated
otherwise) with continuous low speed stirring. The intrinsic fluorescence increase from Gαt
was measured with the PerkinElmer Life Sciences LS 50B luminescence spectrophotometer
employing excitation and emission wavelengths at 300 and 345 nm, respectively, as described
(32-36). No signals from Rho in the absence of Gt were detected in the control experiment.
Histology and Immunocytochemistry—Canine retinas were prepared for morphological studies
either by a triple fixation protocol (37) before embedding in plastic or by 4% paraformaldehyde
fixation for cryosectioning and immunocytochemistry after optimal cutting temperature
compound embedding. For immunocytochemical studies, sections from optimal cutting
temperature compound-embedded retinas were labeled with monoclonal antibody K16-107C,
directed against the C-terminal domain of opsin (provided by Dr. P. A. Hargrave) (28), and an
anti-RPE65 peptide polyclonal antibody (provided by Dr. T. M. Redmond).
Modeling—Dog WT and mutant Rho models were built from the Protein Data Bank code
1HZX crystal structure. The loops not present in the Rho crystal structure were created using
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the Modeler module (38) of Insight II Version 2000 (Accelrys, San Diego, CA). Verification
of the created loops and of the whole structure was accomplished with the Profile-3D module
(39) by evaluating the compatibility between sequence and structure. The resulting structures
were embedded in dipalmitoylphosphatidylcholine membrane. Optimization of energy and
molecular dynamics was conducted using the CVFF Forcefield in Insight II for both WT and
T4R mutant Rho.

RESULTS
Mutation T4R—The T4R opsin mutation affects the region that is sequestered in the intradiscal
space (Fig. 1A). The structures of WT and T4R Rho appear to be almost identical, as predicted
from molecular dynamics (Fig. 1A). The T4R mutation does not influence the anchoring of
Rho in the membrane because residue 4 is located very close to the intradiscal tip of Rho and
is far from the membrane. Instead, Arg4 points its charged group outside Rho and interacts
with the adjacent Glu5. The intradiscal surface in WT Rho is mostly negatively charged, and
once mutated, the additional positive charge of Arg4 or differences in protein folding in the
vicinity of this region prevent glycosylation at Asn2 (Fig. 1A, upper and middle panels, red).
The extracellular region of Rho is highly conserved among mammalian opsins, and a number
of pathogenic mutations in mammals leading to autosomal dominant RP have been identified
(Fig. 1B). Two sets of mutations will affect glycosylation at Asn2 and Asn15 either by
substitution of these residues with a residue that cannot be glycosylated or by elimination of
consensus sequences that are essential for recognition by endoplasmic reticulum
oligosaccharyltransferase. It is unclear how mutations in the intradiscal region affect
oligomerization of Rho (Refs. 40-43; see also Ref. 4).
Mutant Opsin Accelerates Degeneration—Dog T4R opsin is more toxic to photoreceptor cells
than Rho, as shown in the following genetic experiment. The absence of the retinal
chromophore correlates with an increased toxicity of the protein. The fundus of the left eye of
an 8-month-old affected RHOT4R/+ dog appeared to be within normal limits, with uniformly
normal morphology and no ophthalmoscopic evidence of retinal degeneration (Fig. 2,A1-A3).
It should be noted that older animals (>10 months) begin to exhibit severe retinal degeneration,
initially in distinct topographic regions that later become more generalized (22). Fundus
photomontages of the left eye of a 6.5-month-old RHOT4R/+ RPE65−/− dog, which could not
produce the chromophore because of mutation in the RPE65 gene (24,25,44), displayed
hyperreflectivity of the tapetal fundus (Fig. 2B1), moderate vascular attenuation, and changes
characteristic of outer retinal thinning and mid-stage disease. This fundus appearance reflects
the photoreceptor degeneration present uniformly throughout the double mutant retina, as
shown in histological sections in Fig. 2 (B2 and B3).
RHOT4R/T4R Dog Has a Normal Level of Visual Pigment—Retinal immunocytochemistry of
a 2-month-old homozygous affected RHOT4R/T4R dog showed normal morphology and ROS
formation (Fig. 3A). The retina from a RHOT4R/T4R dog was employed to isolate Rho by affinity
chromatography or retinoids by analytical techniques in our studies. UV-visible absorption
spectra of immunoaffinity-purified WT and T4R Rho showed almost identical spectra and
A280 nm/A500 nm ratios of 1.70 and 1.72, respectively (Fig. 3B), suggesting that the mutation at
this position does not affect the location of the intradiscal E2 loop of Rho, which comes close
to the chromophore core (8,45). As assessed by silver staining, WT Rho and its mutant were
purified to apparent homogeneity (Fig. 3B, right panel). The amounts of Rho as measured by
UV-visible spectroscopy of complete extracts from dog retina in WT, RHOT4R/+, and
RHOT4R/T4R eyes were comparable (Fig. 3B, left panel, inset). Similarly, the quantities of 11cis-retinal, identified by specific elution time and spectral properties (29,30), in WT,
RHOT4R/+, and RHOT4R/T4R retinal extracts were equal to values of 2.8, 2.65, and 2.5 nmol/
eye, respectively (Fig. 3C, upper panel, inset). These results agree with the histological data.

J Biol Chem. Author manuscript; available in PMC 2006 January 26.

Zhu et al.

Page 8

The elevated all-trans-retinyl esters in the RHOT4R/T4R animal were within observed
differences between individual dogs.
T4R Rho Is Not Glycosylated at Asn2—The glycosylation status of T4R Rho in extracted and
purified Rho was evaluated by SDS-PAGE (Fig. 4A) and immunoblotting (data not shown).
Rho from WT retina displayed a single band and predictably had two glycosylation sites; Rho
from the RHOT4R/+ retina had two bands indicating two forms of Rho, one with mobility equal
to that of WT Rho and the other with higher mobility, suggesting only partial glycosylation.
T4R Rho from RHOT4R/T4R retina displayed a single band, most likely only singly glycosylated
Rho. When Rho from WT, RHOT4R/+, and RHOT4R/T4R dogs was deglycosylated, the proteins
had identical mobilities, which were somewhat faster than that of unmodified T4R Rho. All
Rho samples moved faster after deglycosylation (Fig. 4B), suggesting that the Rho mutant is
properly glycosylated at only a single site. Because the disease manifests regional differences
in dog retina, we investigated whether there is a regional difference in the glycosylation.
Immunoblotting of Rho from different quadrants showed very similar patterns (Fig. 4C),
suggesting that there is no variability in glycosylation in the different sectors of the eye.
T4R Rho was in-gel digested with trypsin, and the released peptides were analyzed directly by
LC-MS/MS. Interestingly, MS/MS data revealed that the standard and the sample gave m/z
values of 520.1964 and 520.2368, respectively, corresponding to the Ac-MDGR peptide
(calculated precursor ion monoisotopic mass for [M + H]+ = 520.2184), which is the
deaminated product of the authentic tryptic Ac-MNGR product (calculated monoisotopic mass
for [M + H]+ = 519.2354). Both MS/MS spectra were almost identical, and the y ions series
(y1–y4) could be fully observed together with some a ions and z ions or y ion-NH3 (Fig. 5, A
and B). The strongest evidence of the presence of Ac-MDGR instead of Ac-MNGR came from
y2 and y3, with the indication of the loss of a nominal mass of 115 Da (Asp). The observed
fragmentation pattern is in agreement with the sequence Ac-MDGR. The same peptide was
also identified with another trypsin from a different supplier (Worthington). Thus, this tryptic
peptide is unexpectedly deaminated by trypsin. This does not change, however, the conclusion
drawn from the analysis. Our results demonstrate clearly that the Asn residue in the second
position of the T4R Rho mutant is not glycosylated.
T4R Rho Releases the Chromophore Faster than WT Rho—To study the release of retinal,
immunoaffinity-purified WT Rho (Fig. 6, A and C) and T4R Rho (Fig. 6, B and D) were
bleached in the presence and absence of NH2OH. No significant differences were observed.
However, when the chromophore was trapped in the protonated Schiff base linkage with
H2SO4, a smaller absorption peak was observed in the T4R Rho sample (∼80% compared with
WT Rho), suggesting that the chromophore after bleaching in T4R Rho was not as effectively
retained in the binding site as in WT Rho (Fig. 6, A and B, blue traces).
We further measured the trapping of the chromophore in the binding site. The decay of Meta
II was monitored (Fig. 7A) using a fluorescence assay that takes advantage of the increase in
fluorescence when the chromophore leaves the binding pocket (32,34). Meta II of T4R Rho
decayed faster in the presence and absence of NH2OH than did Meta II of WT Rho (Fig. 7B).
When the data were fitted to a first-order reaction, the time constants were calculated to be τ
= 33.3 min for WT Rho and τ = 12.2 min for the mutant (Fig. 7C).
Dog mutant Rho was also less thermally stable than WT Rho (Fig. 8A). This difference in
stability was diminished when a strong nucleophile (NH2OH) was added (Fig. 8B). The lack
of stability against NH2OH is likely due to differences in the amino acid sequence within the
chromophore-binding site of dog versus bovine Rho (Fig. 1B).
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Regeneration in digitonin revealed another striking difference between dog WT and T4R Rho.
In this detergent, T4R Rho regenerated slowly compared with WT Rho (Fig. 9). Similar
differences were also observed in DM (data not shown). However, it should be noted that Rho
regeneration took place in vivo in membranes (Fig. 3). The use of mild detergent may
exacerbate the effect of mutation, uncovering more clearly the harmful effect of the mutation.
The Intradiscal Region of T4R Rho Is Less Structured—To investigate whether the intradiscal
region is misfolded, limited proteolysis was employed. Trypsin cleaves the peptide bond at the
C-terminal side of Arg or Lys when either is in an open configuration that can insert into the
binding site of the protease. When Rho digestion was compared by SDS-PAGE and
immunoblotting using anti-Rho C terminus and anti-Rho N terminus antibodies, major
differences were observed (Fig. 10). WT Rho and T4R Rho lost only the C-terminal region as
described previously (46) and were visualized by the anti-Rho N terminus antibody (doublet
at ∼36 kDa) (Fig. 10, B and E), as the C-terminal cleavage abolished recognition by the antiRho C terminus antibody (single band at ∼36 kDa). In contrast to Rho, opsins were degraded
much faster, as many low molecular mass species of the degraded proteins were observed. The
N terminus of T4R opsin was digested much faster (Fig. 10E) than WT opsin (Fig. 10B). These
differences could be a result of both the point mutation and the single glycosylation of T4R
opsin. These results suggest that the N terminus is primarily affected, leading to the loss of
recognition by the anti-Rho N terminus antibody.
Rho*-Gt Binding and Activation—Next, the interactions between Gt and WT or T4R Rho*
were investigated (Fig. 11, A–C). Once formed, the Rho*-Gt complex had a higher molecular
mass than either Gt or Rho itself and migrated faster through the size exclusion chromatography
column. When run through the column alone, Gt eluted in fractions 35–43 (data not shown).
In the Gt binding experiments, together with either bleached WT Rho or T4R Rho, Gt was
mainly present in fractions 33 and 35 (Fig. 11A, upper panels), indicating that the complexes
were formed. However, Gt was also present in fractions 37 and above, co-eluted with a
proportional amount of opsin. In the presence of GTPγS (non-hydrolyzable analog of GTP),
the dissociation of Gt from WT or T4R opsin was observed as Gt shifted toward the later
fractions (fractions 37-39) (Fig. 11, A and B, lower panels). Gt dissociated more slowly from
the T4R opsin complex than from the WT opsin complex, given the observation of the relative
lag in the elution of Gt with T4R opsin. This suggests that the possible conformational change
in the T4R mutant may play a role in either stronger binding or slower release.
In the Gt activation assay, which monitors the rate of change in intrinsic fluorescence from
Gαt (47,48), we obtained a much slower initial rate with T4R Rho* at either neutral or slightly
acidic pH (Fig. 11C). WT Rho displayed a faster initial activation rate at neutral pH compared
with slightly acidic pH, whereas the T4R mutant showed the opposite trend. The slower
activation may be partially related to the faster decay of Meta II for the mutant. This observation
was further supported by the experiment in which there was no GTPγS added until Rho* and
Gt were incubated together for the measured relaxation time for the T4R mutant (τ = 12.2 min).
There was little or almost negligible increase in the fluorescence of Gαt upon addition of
GTPγS when Rho* decayed (Fig. 11C, gray trace). These results are consistent with the
relaxation time measured; since most of the Meta II is consumed by that time, Gt activation is
expected to be much slower. The apparent initial rates calculated from each group of
experiments were as follows: WT Rho at pH 7.5, k0 = 0.0026 s−1; WT Rho at pH 6.0, k0 =
0.0019 s−1; T4R Rho at pH 6.0, k0 = 0.0013 s−1; T4R Rho at pH 7.5, k0 = 0.0005 s−1; and T4R
Rho at 800 s > τMeta II at pH 7.5, k0 = 0.0003 s−1. Together, the lack of activation as measured
by the fluorescence assay and the differences in the gel filtration of the complexes indicate that
the T4R Rho*-Gt interaction is aberrant.
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DISCUSSION
In this study, we investigated the properties of T4R Rho isolated from affected canine retinas;
Rho was synthesized, processed, and trafficked in its native host cells, the rod photoreceptors.
The main points of our experiments include the following. 1) The T4R mutation eliminates
sites of recognition at Asn2 by oligosaccharyltransferase throughout the dog retina, but it
appears that Asn15 is glycosylated similarly compared with WT Rho. The lack of glycosylation
at Asn2 does not prevent transport of the mutant protein to ROS and its regeneration. The full
complement of Rho is found in the dark-adapted animals. 2) The deleterious effect of the T4R
mutation is likely mediated by opsin rather than by Rho. This difference, evident in multiple
biochemical assays, was confirmed by the genetic experiment combining the T4R Rho
mutation with the RPE65 knockout mutation. In double mutant dogs, the RPE65 mutation leads
to a lack of chromophore production and greatly accelerated retinal degenerative disease
compared with the single mutant T4R retina. 3) Mutation at the N terminus affects the
chromophore-binding site, as the release of the chromophore is accelerated, and in vitro
regeneration with 11-cis-retinal is inhibited; the mutation also affects formation of the active
Gt conformation and the prompt release of activated Gt. It is clear that solubilization of Rho
in mild detergent exacerbated these differences compared with native T4R Rho in membranes.
However, the visual process happens repeatedly in vivo, whereas in the purified system, it is a
one-time process. The lower thermal stability of the mutant may further aggravate the inherited
instability of opsin in vivo.
Dog Versus Bovine Rho—As expected, the general properties of canine Rho studied here and
bovine Rho from a number of previous studies were similar. The glycosylation of dog WT Rho
was uniform as judged by SDS-PAGE, which is similar to that of bovine Rho isolated from
retina. No differences in regeneration or glycosylation were observed in different parts of the
dog retina. In contrast, Rho expressed in heterologous systems was heterogeneously
glycosylated. Without any amino acid changes on the cytoplasmic surface implicated in
binding Gt (49,50), dog WT Rho effectively stimulated bovine Gt. Bovine and dog Rho display
similar bleaching properties, but due to nine changes within the chromophore-binding site (Fig.
1A, lower panel), the half-life for chromophore release is ∼33 min for dog Rho (Fig. 7)
compared with ∼15 min for bovine Rho (Ref. 32 and confirmed in our assay). Dog Rho was
less stable with respect to NH2OH, again likely due to the differences in the amino acid residues
within the chromophore-binding site.
In contrast, dog T4R Rho undergoes a different bleaching pathway, as the photoactivated
mutant has a reduced ability to activate Gt, likely in part because its photoproduct
corresponding to Meta II decays approximately three times faster compared with WT Rho. The
binding of Gt to T4R Rho photoproduct(s) appears also to form an aberrant nonproductive
complex that could be detrimental to the physiology of the photoreceptors and ultimately lead
to their demise. The nature of the deviant interaction between Gt and the T4R mutant has not
been explained at the mechanistic level or correlated with cell physiology in this study.
Structural Considerations—The electrostatic potential of the N-terminal region in WT Rho is
negative due to the presence of Glu5. Introduction of Arg4 changes the positively charged
distribution and may prevent glycosylation at Asn2. However, it is somewhat surprising that
the mutation on the intradiscal surface of the protein affects the chromophore-binding site and
ultimately the cytoplasmic surface. We note that the P23H mutation on the intradiscal surface
produces a hydrophilic channel in the interior of the protein that could accommodate water
molecules and allow the hydrolysis of the covalently bound chromophore (14). Also, in the
case of T4R, the chromophore appears to be destabilized by mutation in this general region.
Both observations underscore the importance of the “plug” in maintaining the location of the
chromophore and protecting it from hydrolysis (3).
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In tissue culture, non-glycosylated opsin folds correctly as demonstrated by its normal
palmitoylation, transport to the cell surface, and pigment formation with 11-cis-retinal (19).
Similar to the T4R mutant described here, non-glycosylated Rho shows less efficient lightdependent activation of Gt. Using multiple substitutions that abolish glycosylation at Asn2 and
Asn15 and reduced Gt activation, it was suggested that glycosylation of Rho at Asn15 is more
important in signal transduction (19). Additionally, it was correctly deduced that the extracellular region is involved in the formation of a specific structure, at present known as the plug
(8). Bleaching of glycosylated and non-glycosylated Rho results in similar photo-bleached
products as determined by absorption spectra, but non-glycosylated Rho is inefficient in Gt
activation (19). Similarly for the dog T4R Rho mutants, the lack of glycosylation at Asn2 and
the introduction of the positive charge within this structurally sensitive region (Fig. 1A,
upper and middle panels) are likely to be detrimental to protein stability and regeneration.
Although bleaching appeared to be nearly normal, the signaling state of T4R Rho is clearly
aberrant.
Congenital Night Blindness Versus RP Rho Mutants—Similar phenotypes as observed for dog
T4R Rho could be more common and related to other Rho mutants characterized previously.
Janz et al. (51) noticed an ion pair between Arg177 and Asp190, near the highly conserved
disulfide bond in the extra-cellular region. This ion pair is found in almost all vertebrate opsins
(Ref. 51; reviewed in Ref. 52). The ion pair opsin mutants regenerate with 11-cis-retinal and
couple to Gt. However, they are thermally unstable in the dark state because of rapid hydrolysis
of the retinal Schiff base linkage, indicating that the extracellular E2 loop encompassing this
particular ion pair is important for Rho stability. This observation suggests that the Asp190
mutant, observed in a subset of RP patients (53), may be thermally unstable and results in
photoreceptor degeneration.
In addition, congenital night blindness mutants that are characterized by an open conformation
of the chromophore-binding site for nucleophiles have been identified. For example, T94I opsin
folds properly and binds 11-cis-retinal to form pigment, but T94I Rho displays reduced thermal
stability, has a long lived Meta II photostate, and shows highly increased reactivity toward
NH2OH in the dark compared with WT Rho (54,55). In addition, it has been shown that T94I
opsin is constitutively active (55). The abnormal function of this Rho mutant is likely related
to the decreased thermal stability and opsin constitutive activity without protein misfolding.
This property differentiates these and other congenital night blindness mutants (Refs. 55 and
56; reviewed in Ref. 57) from the structurally unstable mutants like T4R Rho described in this
study or the previously mentioned RP Asp190 Rho mutant (53). Interestingly, the most common
RP mutant, P23H Rho, in addition to structural changes (14), is also less stable than the WT
protein (15).
Potential Retinoid Supplementation and Lower Light Exposure May Counteract the RHOT4R
Mutant—As both the mouse and human age, there is a decline in the rate of Rho regeneration
(reviewed by Jackson et al. (58)), which ultimately leads to photoreceptor loss (59). This
process likely extends to dogs as well. Therefore, as the animal ages, more and more of the
T4R opsin that is unstable will be generated, leading to progressive destruction of ROS disc
structure. The defect is relatively mild, and only when a certain threshold is reached is there a
sectorial massive degeneration. Based on the results obtained with double mutant animals that
lack the enzymatic pathway for retinoid production through the retinoid cycle (reviewed by
McBee et al. (60)), it is likely that light will further exacerbate the problem in the presence of
the T4R mutation (Fig. 2). This would also apply to the T4K mutation, and lower light exposure
and dietary supplementation with the photoactive chromophore may be therapeutic for RP
patients with this class of mutations.
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Interestingly, supplementation of 15,000 IU of vitamin A taken daily slows the progression of
the common forms of RP as monitored by electroretinogram testing (61,62). Because of
heterogeneity of the RP mutations, it was important to correlate these findings with specific
amino acid substitutions. This study has been extended to the specific T17M Rho mutation. Li
et al. (63) found that vitamin A supplementation slows the rate of photoreceptor degeneration
in mutant mice carrying this Rho mutation. In addition, supplementation with cis-retinoids also
improves cell targeting of P23H Rho under tissue culture conditions (14,15,64). Thus, this
simple but potentially effective therapy deserves more attention and further improvements.
Novel Properties of Pathological Mutant Opsin—Opsin with a mutation that causes autosomal
dominant RP may lead to an aberrant product that may, in turn, exhibit constitutive activity
(65), have aberrant vectorial transportation (66), or misfold during biogenesis (14,64,67-69).
The T4R mutation is characterized by opsin instability and may only manifest at a later stage
of the disease when the supply of 11-cis-retinal is inhibited by the aging process or when the
photoreceptors are exposed to intense light. We attribute these differences between the WT
and T4R opsins to the positive charge at Arg4 resulting from the mutation and not the
subsequent lack of glycosylation at Asn2, as bovine deglycosylated Rho in our assays showed
very similar properties to WT Rho. However, lack of glycosylation at Asn15 may cause other
cell biological problems, as a substitution of Ser for Asn (N15S) was identified in a patient
with autosomal dominant RP (70,71). In the case of human N15S and dog T4R mutations, the
degeneration occurs within distinctive topographic regions (sectorial RP) (22,70-72) that could
be related to differences in light exposure. Detailed analysis of patients with the T4K mutation
is needed to further support this hypothesis.
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Fig. 1.

Models of WT and T4R Rho. A, three-dimensional models of WT (upper panel) and T4R
mutant (middle panel) Rho embedded in phospholipid bilayers. The model of oligomeric WT
Rho in the membranes was described previously (41), and it is based on the crystal structure
of bovine Rho (8). Only the first shell of phospholipids is shown. The electrostatic potential is
mapped onto the rhodopsin surface. Red denotes negatively charged areas, and blue denotes
positively charged areas. The T4R mutation changes the charge distribution around Asn2,
making its surroundings positive and preventing glycosylation at this site. The electrostatic
potential is nearly unaffected at the Asn15 site. Lower panel, detailed view of the intradiscal
domain of T4R Rho. Arg4 likely forms an ion pair with Glu5. B, two-dimensional model of
Rho for bovine (black), human (green), mouse (blue), and dog (red). Mutations associated with
autosomal dominant RP (ADRP) are on a black background, whereas those associated with
autosomal recessive RP (ARRP) are on a gray background. The T4R and T4K point mutations
are shown on a red background. Note that T4R Rho found in dogs (22) resembles RP mutation
T4K in man (16), possibly affecting glycosylation at position 2.
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Fig. 2.

Fundus photography and retinal morphology of affected dogs. A1, photomontage of the
interior posterior surface of the eyeball, including the retina, optic disc, macula, and posterior
pole (fundus) of the left eye of an 8-month-old affected RHOT4R/+ dog. The fundus is normal.
A2, retinal morphology of the central superior (tapetal) region of the retina of the right eye of
the same dog. A3, retinal morphology of the peripheral region of the same dog. The retina is
uniformly normal morphologically. B1, fundus photomontage of the left eye of a 6.5-monthold RHOT4R/+ RPE65−/− double mutant dog. There is hyperreflectivity of the tapetal fundus
(indicative of retinal thinning) and moderate vascular attenuation, changes typical of mid-stage
progressive retinal atrophy. B2 and B3, superior and inferior retinas, respectively, of a 6.5month-old RHOT4R/+ RPE65−/− double mutant dog. Mid-stage outer retinal degeneration is
present uniformly throughout the double mutant retina. Scale bars = 5.0 mm (A1 and B1) and
50 μm (A2, A3, B2, and B3).
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Fig. 3.

Localization and quantification of Rho in the retina of aRHOT4R/T4R mutant dog and
retinoid analysis. A, retinal immunocytochemistry of a frozen section from the right eye of a
3-month-old homozygous affected RHOT4R/T4R dog. Opsin is shown in green, and the retinal
pigment epithelium protein RPE65 is in red. RPE, retinal pigment epithelium; OS, outer
segment; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner
nuclear layer; IPL, inner plexiform layer. Nuclei were visualized by staining with Hoechst
33342 dye (blue). Scale bar = 50 μm. B, UV-visible absorption spectra (left panel) and silverstained SDS-polyacrylamide gel (right panel) of immunoaffinity-purified WT and T4R Rho.
The asterisks indicate SDS-induced oligomers of Rho and the mutant. Inset, the amount of
Rho solubilized in 1% DM, 150 mM NaCl, and 10 mM bis-tris propane (pH 7.5) from one retina
of a WT, RHOT4R/+, or RHOT4R/T4R dog. The amounts of Rho were measured in three
independent experiments from which the standard deviations were calculated. The retinas were
harvested from 3-month-old dogs for all three genetic backgrounds. Au, absorbance units. C,
retinoid composition of WT, RHOT4R/+, and RHOT4R/T4R dog retinas in the superior central
region (one-sixth of the eye surface) analyzed by HPLC. Peak 1, all-trans-retinyl ester; peak
2, syn-11-cis-retinal oxime; peak 3, syn-all-trans-retinal oxime; peak 4, syn-9-cis-retinal
oxime; peak 5, syn-13-cis-retinal oxime; peak 6, 11-cis-retinol; peak 7, all-trans-retinol; peak
2′ and 3′, anti-isomers of the corresponding compounds, respectively. The asterisk indicates
influence from change of the solvent (for details, see “Experimental Procedures”). Proportional
amounts of retinoid between genetic backgrounds were found in 3-mm retina punches or in
extracts from whole eyes. mAu, milli-absorbance units.
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Fig. 4.

Glycosylation status of T4R Rho. A, glycosylation status of extracted and purified Rho from
dogs of different genetic backgrounds with respect to Rho mutation. The Coomassie Bluestained SDS-polyacrylamide gel shows supernatant solubilized in 1% DM (left) and
immunoaffinity-purified Rho (right) from WT, RHOT4R/+, and RHOT4R/T4R dog retinas. B,
immunoblot of immunoaffinity-purified Rho. Rho from WT, RHOT4R/+, and RHOT4R/T4R dog
retinas before and after deglycosylation with peptide N-glycosidase F (PNGase F) was detected
with anti-Rho C terminus antibody 1D4. C, immunoblot of Rho from different quadrants of
WT, RHOT4R/+, and RHOT4R/T4R dog retinas. Similar results were obtained in three to five
independent experiments. SN, superior nasal; ST, superior temporal; IN, inferior nasal; IT,
inferior temporal.
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Fig. 5.

LC-MS/MS analysis of tryptic N-terminal peptides. Shown are the results of analysis using
the standard synthetic peptide Ac-MNGREGPNGYV (A) and immunoaffinity-purified T4R
Rho (B). The expected product, Ac-MNGR, [M + H]+ at m/z 519.2354, was not observed, but
instead, its deaminated product, Ac-MDGR, [M + H]+ at m/z 520.2184, was detected in both
cases. Both MS/MS spectra of Ac-MDGR at m/z 520.2310 from the standard (A) and at m/z
520.1900 from T4R Rho (B) were nearly identical. The characteristic fragments for calculated
m/z values are as follows: y4 , 520.2184; y3, 347.1673; y2, 232.1404; y1, 175.1189; z3- or y3NH 3, 330.1408; z1- or y1-NH3, 158.0924; a3-H2O, 300.0970; and a1, 146.0640. The structure
at the top shows the fragmentation patterns of this tetrapeptide. The analysis was reproduced
in two independent experiments. The deamidated residue is shown in gray.
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Fig. 6.

UV-visible spectra of WT and T4R Rho after bleaching. Immunoaffinity-purified WT Rho
(A and C) and T4R Rho (B and D) were bleached for the indicated times without (A and B) or
with (C and D) 20 mM neutral NH2OH. In A and B, the pH of the samples was adjusted to 1.9
with H2SO4 to protonate the Schiff base. The bleaching of WT and T4R Rho was similar,
whereas the amount of acid-trapped retinylidene-opsin was lower in the Rho mutant. Similar
spectra were obtained in three independent experiments.
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Fig. 7.

Meta II decay of WT and T4R Rho. A, shown are the fluorescence emission spectra of WT
Rho (left panel) and T4R Rho (right panel) before (black trace), immediately after (dark gray
trace), and after thorough (light gray trace) photobleaching. B, the decay of WT Rho (black
trace) and T4R Rho (red trace) Meta II was recorded with (lower panel) or without (upper
panel)10mM NH2OH at pH 6.0. Similar results were obtained in five independent experiments.
C, the data from B without NH2OH were fitted to a first-order reaction, which gives the
relaxation times (τ) of WT Rho (left panel) and T4R Rho (right panel) Meta II as 33.3 and 12.2
min, respectively. Similar results were obtained in five independent experiments.

J Biol Chem. Author manuscript; available in PMC 2006 January 26.

Zhu et al.

Page 22

Fig. 8.

Stability of WT and T4R Rho. The stability of Rho was measured as a change in the UVvisible absorption spectra at its absorption maximum at 37 °C without (A) or with (B) 20 mM
neutral NH2OH. The results were plotted assuming 100% absorption at the initial point. Bovine
Rho was used as a control for the NH2OH sample. Similar results were obtained in three
independent experiments.
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Fig. 9.

Regeneration of WT and T4R Rho in digitonin. 11-cis-Retinal was added in 50-fold excess
to the purified opsins solubilized in 2% digitonin, 10 mM bis-tris propane, and 500 mM NaCl
(pH 7.5). UV-visible spectra were recorded as a function of time, and the data were then fitted
to a pseudo first-order reaction: ln(A0 − X) = −k′t + C, where X is the absorbance at 500 nm at
any given time and A0 is the absorbance at 500 nm before Rho was bleached. WT opsin
regenerated at a rate ∼30 times faster than the T4R mutant. Regeneration reached the level of
∼70% compared with the starting amount of Rho.
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Fig. 10.

Limited proteolysis of WT and T4R Rho. At a 200:1 molar ratio of Rho to trypsin,
immunoaffinity-purified WT (A–C) or T4R (D–F) opsin (second through sixth lanes) or Rho
(seventh through tenth lanes) was trypsinized for the indicated times (0, 5, 15, 30, and 45 min)
at room temperature. Opsin was generated from Rho by bleaching with a Fiber-Lite illuminator
for 5 min at room temperature in the presence of 20 mM neutral NH2OH. A and D, silver-stained
SDS-polyacrylamide gels; B and E, anti-Rho N terminus antibody B6-30N immunoblots; C
and F, anti-Rho C terminus antibody 1D4 immunoblots. The arrows indicates the trypsin band.
Similar digestion patterns were obtained in three independent experiments.
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Fig. 11.

Gt activation assay with WT and T4R Rho*. A and B, Gt incubated with Rho* (see
“Experimental Procedures”) was submitted to size exclusion chromatography, and the resulting
fractions were examined by immunoblotting with anti-Rho C terminus antibody 1D4 (upper
panels) or anti-Gα and anti-Gβt antibodies (lower panels). Fraction numbers are indicated.
Similar results were obtained in three independent experiments. In B, GTPγS was present in
the samples before loading onto the column. In A and B, the arrows inside the box represent a
molecular mass marker of 38.5 kDa. The asterisks denote the fractions with the highest protein
content. C, the intrinsic fluorescence Gt assay was performed with WT Rho at pH 6.0 (black
trace) and pH 7.5 (blue trace) and with T4R Rho at pH 6.0 (red trace) and pH 7.5 (green
trace) and upon incubation 800 s before addition of GTPγS at pH 7.5 (gray trace) at a 1:10
molar ratio of Rho to Gt. The apparent initial rates after curve fitting were calculated as follows:
WT Rho at pH 7.5, k0 = 0.0026 s−1; WT Rho at pH 6.0, k0 = 0.0019 s−1; T4R Rho at pH 6.0,
k0 = 0.0013 s−1; T4R Rho at pH 7.5, k0 = 0.0005 s−1; and T4R Rho at 800 s > τMeta II at pH
7.5, k0 = 0.0003 s−1. The initial Gt activation rates were calculated from three independent
experiments under each condition.
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